Fight against novel coronavirus pneumonia! Klitschke, Shuanghuanglian, redceway

Organize Linan According to the official website of the National Health Commission, as of 24:00 on February 11, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 38800 confirmed cases (8204 of which are severe cases), and 4740 discharged cases have been cured In 2020 novel coronavirus pneumonia (novel coronavirus novel coronavirus pneumonia) epidemic situation often affects the hearts of the Chinese Now scientists and medical workers in the whole country are fighting against the new crown pneumonia Novel coronavirus pneumonia is also blocked by effective prevention and control measures, vaccines being developed, and the spread of the disease cannot do without the development of symptomatic drugs or even specific drugs The novel coronavirus pneumonia has been paid attention to by the pharmaceutical industry and the public in the treatment of new crown pneumonia We have summarized the latest information on these drugs Lopinavir, an anti HIV drug, was originally developed by ibuprofen Novel coronavirus, a member of the national expert group and director of respiratory and critical care medicine, Wang Guangfa, told the media in January 23rd that "an anti HIV drug named" RNA "is effective because it is RNA virus like HIV and may be used in the process of virus replication and assembly Some similar protein functions, so the use of anti HIV drugs can show some effect " Since then, novel coronavirus pneumonia may be effective by many experts, and the national treatment plan mentioned that it can be used for treatment During the novel coronavirus pneumonia, he was caught in hot search On January 31, Guo xushun's team from school of medicine, Sun Yat sen University published the title of "molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to Wuhan pneumonia coronavirus" online at birxiv The research paper of "proteases" also mentioned that the researchers think that the therapeutic effect of Coriolis on Wuhan pneumonia may be mainly due to the inhibition of ritonavir on the coronavirus endopeptidase C30 However, klitschke, who became popular accidentally, is not a specific drug at present A novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) released by the National Health Protection Commission in February 5th, was explicitly mentioned in the antiviral therapy, adding that "there is no effective antiviral therapy at present." Add "or add ribavirin" on the basis of α - interferon atomization inhalation and lopinavir / ritonavir At the same time, we should pay attention to the adverse reactions of lopinavir / ritonavir, such as diarrhea, nausea, vomiting, liver function damage, and the interaction with other drugs In January 31st, novel coronavirus was found in Wuhan virus Institute and Shanghai research team of Chinese Academy of sciences through laboratory in vitro test It is confirmed that micro-blog has the effect of inhibiting new coronavirus The next step is to confirm it by further clinical research The news was released late at night, which caused a huge uproar Many people lined up overnight to buy double coptis Although the research is only preliminary and has not been clinically verified, it seems to be a "life-saving straw" for people in the stage of epidemic panic What's more worrisome is that some people regard Shuanghuanglian as a preventive drug, while Shuanghuanglian is a kind of double antidote on the list of clearing away heat and detoxification, which is not suitable for all people to eat Some studies have proved that blind use of Shuanghuanglian without the guidance of doctors may have great side effects Because the public misunderstood "inhibition" as "prevention", a large number of rush to buy, many local pharmacies, pharmacies Shuanghuanglian sold out overnight In response to the Shuanghuanglian incident, academician Zhang Boli, an expert of the central guidance group to Hubei Province, responded In an interview with the media, Zhang Boli pointed out that "a lot of traditional Chinese medicines for clearing away heat and detoxifying have antiviral effects There is evidence in pharmacology and clinical practice, and there is nothing new Shuanghuanglian has Shuanghua, huangcen and forsythia prescriptions, including many similar drugs of these tastes, such as compound honeysuckle granules, antiviral oral liquid, Lianhua Qingwen capsule, Reduning, etc They all have antiviral effects and are broad-spectrum, not specific " Zhang Boli said that novel coronavirus oral liquid has been approved for sale, and it is a symptomatic treatment for new coronavirus The main reason is whether it is effective The treatment of novel coronavirus with Shuanghuanglian is expanding its therapeutic range and is being handled in accordance with expanded indications management Now the first thing is to answer the question of efficacy According to multiple sources, the clinical research of Shuanghuanglian is in progress Li Lanjuan, an academician of the Chinese Academy of engineering and a member of the high-level expert group of the National Committee of the Communist Party of China, announced the latest research results on the treatment of pneumonia caused by the new coronavirus on February 4, Changjiang Daily reported Preliminary tests showed that in vitro, compared with the untreated control group, abidol at 10-30 micromolar concentration could effectively inhibit the coronavirus by 60 times, and significantly inhibit the pathological effect of the virus on the cells; at 300 micromolar concentration, darunovir significantly inhibited virus replication, and compared with the untreated control group, the restriction efficiency was 280 times According to the database of the State Food and drug administration, abidor has 7 domestic approvals, and the manufacturers are respectively Wuzhong, Ouyi, zhongshuo, Lianshui, siyao and Xiansheng Darunavir is an imported drug of Xi'an Janssen On February 5, Ruikang pharmaceutical said on the interactive platform that the company was concerned about the research results released by Academician Li Lanjuan At present, the company has abidore on sale and sufficient inventory; it has a long-term cooperative relationship with darunavir production enterprises, with smooth purchase and sales channels, and can respond to the use needs of medical institutions at any time As soon as the above research news came out, the concept stocks related to abidore and darunavir were highly sought after in the market, including Ruikang pharmaceutical, Dongyin Co., Ltd., Jiuzhou pharmaceutical, humanwell pharmaceutical, etc According to Sina pharmaceutical, on February 10, Minolta announced that the 18th meeting of the third board of directors of the company had deliberated and passed the proposal on Cooperative R & D and related party transaction with Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd., and agreed that Xuancheng Minolta, the holding subsidiary of the company, cooperated with Nanjing Xiansheng Pharmaceutical Co., Ltd to jointly develop the antiviral API abidol hydrochloride and its He has a variety of antiviral APIs The matter shall be submitted to the general meeting of shareholders for deliberation and approval Novel coronavirus pneumonia was reported to be the first severe case in January 31st The results showed that the treatment of Remdesivir was very effective after receiving Reed's injection, and the symptoms had improved greatly in England Ridcivir is a drug developed by Gilead for Ebola virus, which can inhibit RNA dependent RNA synthetase (RdRp), cut off virus replication and play an antiviral role by inhibiting RdRp synthesis Since then, novel coronavirus pneumonia has been widely expected in the market for Reed Novel coronavirus infection was studied in the hospital in Wuhan on the afternoon of February 5th In the afternoon of February 5th, the team of Wang Chen and Cao Bin of China-Japan Friendship Hospital announced the initiation of remdesivir treatment of 2019 new coronavirus infection, including 761 cases, 308 cases of mild and moderate cases, and 453 cases of severe cases It is expected to complete all clinical work from the end of April to the beginning of May According to another report, as of February 7, the study had been adjusted many times, and Professor Zhao Jianping, an expert of medical treatment group in Hubei Province, released a new clinical grouping scheme, which now tends to be more severe patients The ratio of the former treatment group to the control group was 1:1, and the adjusted treatment group to the control group was 2:1, which means that the subjects had a 66% probability of receiving radcivir treatment Because Gilead published the molecular formula of Ridgeway and other information, which brought convenience to the imitation Sina pharmaceutical noted that on the evening of February 11, Borui biology announced that it had successfully copied and developed the synthesis technology and preparation technology of radcivir API The company has mass produced radcivir API, and the mass production of radcivir preparation is in progress According to the announcement, although Borui pharmaceutical has completed the imitation and preparation production of radcivir API, it still needs to go through clinical trials, drug approval and other links If ridceway is finally transformed into a product to be put into the market, it needs to obtain the authorization of Geely, the original research company, and there will be significant uncertainty in this process Up to now, the cost of Borui pharmaceutical in the development and production of raw materials and preparations of radcivir is estimated to be about 5 million yuan, and it is estimated that another 10 million yuan will be invested in the further scale-up production In the case of novel coronavirus, Reed said that in order to respond to the national call, the drug treatment of new coronavirus should be provided as soon as possible If the product can be approved for marketing, it will be mainly supplied to relevant patients through donation during the epidemic period, which is not expected to have a significant impact on the company's business performance in 2020.